Zoticon funds product development utilizing a unique, off balance sheet financing vehicle which offers attractive advantages over traditional licensing arrangements. Our vehicle typically provides more upside potential then traditional licensing deals while mitigating the risk of internal development. We search globally for innovative product candidates, with a clear goal of accelerating the approval of novel and highly effective products, for their introduction to the global marketplace. We move quickly and effectively to bring products to market.
Zoticon works hard in creating mutually beneficial partnerships. These relationships span the globe and can be for almost any indication. Our entrepreneurial culture and commitment to meeting the needs of patients drives us to explore business opportunities that would be considered “outside the box” of more traditional players.
Zoticon considers a variety of criteria when evaluating potential partnerships. First-rate science is an imperative in any collaboration. Another key factor is a focus on a well-defined patient population with an unmet or underserved medical need, where a new product or service may change the standard of care and provide a strong, positive impact on patients. Zoticon prefers products which have demonstrated clinical safety and efficacy. A strong patent position is also beneficial.
International collaborations are difficult, and Zoticon’s global experience and infrastructure are key strategic assets that bring tremendous value to our partners. We have resources that are fully integrated and work in collaboration with each other and our partners.
Management is composed of a global cross-functional team of industry leaders with expertise and direct operating experience in product development, executive management, clinical medicine, regulatory affairs, sales and marketing, biomedical research as well as corporate finance. The team includes partners and affiliates that are located across the United States, Europe and Israel. Our international presence in centers of innovation allows us to monitor technical breakthroughs and swiftly respond to market opportunities.
Zoticon Bioventures is an off balance sheet investment vehicle which in-licenses late stage clinical compounds into a Special Purpose Development Vehicle (SPDV) in which the licensor receives a significant equity position in consideration for the asset alongside more traditional licensing arrangements such as milestones and royalties. Zoticon then infuses the SPDV with top tiered management as well as capital. The blending of equity compensation as well as traditional royalty arrangements allow the licensor to increase value of the asset through a wide range of possibilities without diluting his own equity or manpower. Also should the drug fail, the licensor is shielded from the brunt of the consequences. The corporate climate at Zoticon is fairly stress free and relaxed. We like to architect deals that are of the win-win variety. We can decide quickly and decisively and so, will not waste unnecessary time of your management.
